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Background: A meta-analysis is needed to comprehensively consolidate findings from the
influence of metformin on IGF-1 levels. The present study was conducted with the objective to 
accurately evaluate the influence of metformin intake on IGF-1 levels via a meta-analysis of
randomized controlled trials.
Methods: A comprehensive systematic search was carried out in PubMed/MEDLINE, Web of























with the 95% CI were applied for estimating the effects of metformin on serum IGF-1 levels.
     
  
     
     
 
         
   
     
       
     
 
   
   






     
    
  
 
Results: 11 studies involving a total of 569 individuals reported changes in IGF-1 plasma
concentrations as an outcome measure. Pooled results demonstrated an overall non-significant
decline in IGF-1 following metformin intake (WMD: -8.292 ng/ml, 95% CI: -20.248, 3.664, p=
0.174) with heterogeneity among (p=0.000,I2=87.1 %). The subgroup analyses displayed that 
intervention duration ˃12 weeks on children (WMD:-55.402ng/ml, 95% CI: -79.845, -30.960, 
I2=0.0%) significantly reduced IGF-1. Moreover, in age 18 ˃ years older metformin intake
(WMD: 15.125 ng/ml, 95% CI: 5.522, 24.729, I2=92.5%) significantly increased IGF-1 than 18 ≤ 
years older (WMD:-1.038 ng/ml,95% CI: -3.578,1.502,I2=78.0%). Following dose-response
evaluation, metformin intake reduced IGF-1 (coefficient for dose-response analysis= -13.14, P=
0.041 and coefficient for liner analysis= -0.066, P= 0.038) significantly based on treatment 
duration.
Conclusion: We found in children, intervention duration ˃ 12 weeks yielded significant reductions 
in IGF-1, whilst paradoxically, in participants >18 years old, metformin intake significantly
increased IGF-1. We suggest that caution be taken when interpreting the findings of this review, 
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1. Introduction
Insulin-like growth factor 1 (IGF-1) is an anabolic hormone produced mainly in the liver. The
hormone plays an important role in regulating biological activities related to growth hormone
(GH), such as insulin metabolism and cell proliferation, differentiation and apoptosis[1]. As such,
IGF-1 has been commonly implicated in various human diseases. For example, an elevated level 
      
  
   
     
 
     
   
      
        
    
   
       
   
     
   
 
   
    
    
  
   
     
   
of serum IGF-1 has been found to be associated with an increased risk of many cancers [2]. In
contrast, a lower level of serum IGF-1 has been associated with diabetes and cardiovascular
diseases[3, 4]. Besides, epidemiological evidence and animal studies have demonstrated the role
of the IGF-1/GH pathway in longevity and aging process[5-9]. These findings indicate that a
proper balance in the level of IGF-1 is essential for optimal health. 
Metformin is an insulin-sensitizing biguanide drug that is commonly used for treatment of type 2
diabetes after dietary and exercise interventions have failed[10]. Metformin has an excellent safety
profile due to its negligible risk of hypoglycemia and clinically-relevant drug interactions (in other 
words, there will be minimal, if any, side effects or changes in the effectiveness of metformin 
when it is used in conjunction with other drugs or agents)[10]. Besides bringing down the level of 
blood glucose, recent evidence has shown that metformin also possesses some anti-cancer 
properties. The use of metformin has been found to be associated with a decreased incidence and
mortality of various cancers[11-13]. Metformin achieves its anti-hyperglycemic and anti-cancer
effects through highly complex mechanisms, which include suppressing the hepatic fatty acid 
oxidation, increasing insulin sensitivity, reducing intestinal absorption of glucose, decreasing
inflammation, and inhibiting mitochondrial oxidative phosphorylation through the LKB1–AMPK 
pathway[14-17]. A number of studies have also demonstrated that metformin induces apoptosis 










For this reason, several studies have been conducted to examine the influence of metformin intake
on the levels of IGF-1 in humans. Nevertheless, different studies have reported inconsistent and
sometimes contradictory findings with regard to the relationship between metformin and IGF-1 
levels. For example, while Cai et al. [21]and Hamed et al. [22]found that metformin intake could 
lead to a significant reduction in IGF-1 level, Díaz et al. [23] and Yates et al. [24] did not find any
significant changes in IGF-1 level following metformin intervention. The conflicting results
    
    
    
     




     
    
     
     
     
 
 
   
   
    
     
    
     
     
obtained in different studies could be attributed to various factors, such as the small sample size in
each individual trial, different characteristics of the study participants, as well as dose and duration 
of metformin intervention. A meta-analysis is needed to comprehensively consolidate findings
from different studies. The present systematic literature review was conducted with the objective




The current study was performed across the PRISMA [Preferred Reporting Items for Systematic
Review and Meta-analysis] protocols [25]. A comprehensive systematic search was carried out in 
PubMed/MEDLINE, Web of Science, SCOPUS and Embase by two independent reviewers (JR
and HKV) from inception until June 2019 without using time or language restrictions. We
considered randomized controlled trials (RCTs) that measured the effects of metformin on












We considered the participant, intervention, comparison, outcome, time, and study design
(PICOTS) criteria to ascertain study inclusion criteria. Endnote Reference Manager X8© was used 
for citation management. Two independent authors (JR and HKV) reviewed the abstract of all
studies to choose eligible trials and subsequently screened the full texts of included studies. The
following inclusion criteria were applied: 1. Trials that had a controlled trial design; 2. Studies
which provided circulating IGF-1 serum in the form of mean differences (MD) with the 95%
confidence intervals (95% CI). In addition, studies not reporting IGF-1 concentrations before and
     
  
 
     
    
      
      
  
 
       
     
    
       
   
 
 
        
   
          
     
      
 
       
   
    
after administration; animal studies; non-randomized study designs; studies without a control
group; reviews, commentaries, conference abstracts and case-reports were excluded.
2.3. Data extraction
Two independent researchers (HKV and JR) extracted the data and an additional reviewer resolved
any disagreements. The following information was retrieved: author, year of publication, country,
number of cases and controls, participants’ gender, mean age (year), study design, duration of
intervention, dose of metformin intervention, and means and standard deviations of IGF-1 levels 
at baseline, post treatment and/or changes between baseline and post treatment. 
2.4. Quality assessment
The Cochrane Collaboration’s tool for quality assessment of randomized controlled trials was used
to assess the risk of bias in all eligible studies (Higgins et al., 2011). The quality assessment tool
encompasses the following domains: allocation concealment, random sequence generation, 
blinding of participants and personnel, incomplete outcome data, blinding of outcome assessment, 











Weighted mean difference (WMD) with the 95% CI were applied for estimating the effects of
metformin on serum IGF-1 levels. When the SD of the mean difference was not provided in the
studies, we obtained it using the following formula: SD change= square root [(SD baseline 
2+SD final 
2) 
-(2×R× SD baseline× SD final)] [26]. Combined WMD from eligible studies was calculated with 
derSimonian and Laird random-effects method. We assessed heterogeneity between study-specific
estimates using the Q-test, the I-squared (defined as significant when a p value < 0.10). Subgroup 
analysis was performed to specify the source of heterogeneity among studies. The potential effects
of metformin dosage and intervention duration were surveyed using fractional polynomial 
modelling in non-linear dose-response analysis and meta-regression analysis. Publication bias was 
    
         
   
    
 
 
   
      
 
       
       
   
 
 
   
    
     
 
   
  
  
      
 
ascertained using funnel plot inspection as well as Egger’s and Begg’s tests. All statistical tests
were executed using the Stata software (Stata Corp. College Station, Texas, USA) and a p value
of 0.05 or less was reported as statistically significant. One-way ANOVA and Tukey-Kramer 
Multiple Comparison tests was used to compare IGF-1 levels and daily metformin intake (mcg/d)
in participants.
3. Results
Primary systematic search identified 560 studies from PubMed/MEDLINE, Web of Science, 
Scopus, and Embase (Supplementary Fig. S1). Duplicated studies were removed and 380 studies
remained. During the primary screening, which was based on review of study titles and abstracts,
338 studies were excluded and 42 studies remained for full text extraction. During the secondary
screening, 31 studies were excluded for the following reasons: 1) non trial design, 2) and studies












Characteristics of the eligible studies are presented in Table 1. one studies were performed in 
China [21], two in Spain [23, 31], two in Italy [28, 34], one in Egypt[22], one in Brazil [30], one
in Sweden [32] , one in Germany [33], and two in USA [27, 29]. All studies were published 
between the years 1999–2018. The mean duration of interventions was 226 days. All studies 
were randomized controlled clinical trials. Dose of metformin intake ranged between 425 and 
2000 mg/day. Studies were conducted on different population three on cancer patients [21, 27, 
28], three on children [23, 29, 31], women with polycystic ovary syndrome[22, 30], one on type
1 diabetes patient [32], and two healthy adults [33, 34]. The results of the quality assessment of
eligible studies are accessible in Table 2. The risk of bias was attributed to randomization 
processes of included studies. 
  
     
   
       
       
    
 
    
   
      
   
    
     
    
  
   
    
   
  
 
    
  
   
       
3.2. Meta-analysis results
11 studies involving a total of 569 individuals (case=279, control=290) reported changes in IGF-
1 plasma concentrations as an outcome measure. Pooled results using the random-effects model 
demonstrated an overall non-significant decline in IGF-1 following vitamin metformin intake
(WMD: -8.292 ng/ml, 95% CI: -20.248, 3.664, p= 0.174; Fig. 1). However, a significant degree of
heterogeneity among studies was observed (p= 0.000, I2= 87.1 %).
3.4. Subgroup analysis
We subsequently stratified studies based on metformin dosage, intervention duration (week), Age
(years) of participants and Type of study population (Table 3). These analyses showed that 
intervention duration (week) and Type of study population were possible source of heterogeneity.
In addition, intervention duration ˃ 12 weeks on children (WMD: -55.402 ng/ml, 95% CI: -79.845   
, -30.960, I2=0.0%) significantly reduced IGF-1. Moreover, in age 18 ˃ years older metformin 
intake (WMD: 15.125 ng/ml, 95% CI: 5.522, 24.729, I2=92.5%) significantly increased IGF-1










3.5. Dose-response and meta-regression
Subsequent analysis of the relationship between intervention duration with plasma IGF-1 
alterations revealed a negative correlation in non-liner dose response (Coefficient for dose-
response analysis= -13.14, P= 0.041; Fig.2) and linear association (Coefficient for liner analysis=
-0.066, P= 0.038). Significant associations were not observed for other outcomes.
3.6. Publication bias and sensitivity analysis
The Begg’s and Egger’s tests did not find a significant publication bias among the studies (p=0.392
and p=0.235, respectively). Evaluation of publication bias by visual inspection of funnel plot
illustrated no evidence of publication bias (Supplemental Fig. 2). To discover the impact of each
single study on the combined effect size, we removed each trial at a time from the analysis and 
       
   
  
     
  
     
 
        
     
      
     
     
     
     
    
       
   
     
    
  
   
    
 
accounted for their individuality. We observed no significant effects of any individual study on
the combined effect sizes.
4. Discussion
It has been asserted that higher IGF-1 bioactivity may be correlated with an increased risk of 
several types of cancer, including prostate [35, 36], colorectal [37], and breast cancers [38]. Given
the potential contrasting roles of the IGF-1 axis on overall indices of health, a deciated effort is
required to better understand the determinants of IGF-1 biological activity, particularly in relation 
to widely used medications. Several studies have investigated the influence of metformin intake
on IGF-1 levels in humans, however, much of the literature is equivocal. For example, while Cai
et al. (Cai et al., 2016) and Hamed et al. (Hamed, Hasan, Ahmed, & Ahmed, 2010) reported that
metformin intake could yield significant reductions in IGF-1 levels, Díaz et al. (Diaz, Bassols, 
Lopez-Bermejo, de Zegher, & Ibanez, 2015) and Yates et al. (Yates et al., 2018) reported contrary
evidence. The incongruent results obtained in different studies could be attributed to various 
factors, such as small sample sizes, varying participant characteristics, in addition to variable doses
and duration of metformin interventions. Clearly, a meta-analysis is warranted to comprehensively
consolidate findings from different studies; thus, the present study sought to evaluate the influence
of metformin intake on IGF-1 levels via a meta-analysis of randomized controlled trials. In accord 
with the aforementioned aim, we found an overall non-significant decline in IGF-1 following 
metformin intake; however, a significant degree of heterogeneity was observed among studies, 
attributable to intervention duration (week) and study population. We found that, in children, 
intervention duration ˃12 weeks led to significant reductions in IGF-1; whilst in participants >18











   
   
       
   
      
 
   
   
 
    
    
  
     
     
   
      
    
  
      
 
 
      
    
Although no, overall, significant effect was manifest, sub-group analyses demonstrated, that when
stratified by age and supplementation duration, significant alterations in IGF-1 were evident. 
Metformin is an insulin-sensitizing biguanide, considered appropriate for treatment of pediatric
type 2 diabetics. The mechanism of action of metformin is multifaceted, where it can facilitate
insulin-induced suppression of gluconeogenesis, moreover, it can induce expression of glucose
transporters, which subsequently increases glucose utilization [39]. We found that longer term
interventions yielded significant reductions in IGF-1 in children, although in independent trials, 
studies have generally reported variable and modest improvements in children when using
metformin for 4–6 months [40-42]. Interestingly, of all the included studies in this meta-analysis,
those that focused on child participants tended to utilize much longer intervention durations, than 
in adult populations. In fact, [29] reported that children with obesity, but no other co-morbidities,
had noticeable increases in highly sensitive C-reactive protein, interleukin 6 (IL-6), fibrinogen, 
and plasminogen activator inhibitor-1 (PAI-1), which represents a pro-inflammatory and pro-
thrombotic state, and is manifest prior to the onset of any other metabolic syndrome symptoms
and the onset of puberty, as compared to normal-weight, age-matched controls [43]. Moreover,
Mauras et al [29] asserted that currently available data support the use of aggressive interventions 
in children, irrespective of other comorbidities, which may conceivably explain the protracted
interventions employed in the included studies. As noted above, a significant degree of 
heterogeneity was observed among studies, which was attributable to intervention duration (week) 











Cancer cells can elicit an increase in the level of insulin circulating in the blood, and stimulate IGF
signaling pathways, which consequently leads to growth of cancerous cells [44]. Metformin elicits
       
       
    
        
   
     
      
     
      
      
       
      
      
      
      




     
      
     
         
       
its therapeutic effect through numerous mechanisms, where it can reduce insulin resistance and
elicit optimal glycemic control [45]. Metformin acts through inhibition of the mTOR pathway;
where autonomous AMP-activated protein kinase (AMPK) is activated, which results in
phosphorylation of tuberous sclerosis complex protein 2. Consequently, this elicits a decrease in
cell growth and protein synthesis [46-48]. Moreover, metformin can reduce HOMA and leptin
levels, respectively, where high concentration of the aforementioned is associated with deleterious 
health outcomes. Leptin purportedly acts on the OB-2 receptor, which can result in activation of
the STAT signaling pathway and, indeed, Ras–Raf MEK signaling. Metformin may indirectly
reduce leptin levels, subsequently inhibiting the OB-2 receptor pathway. Further suggested
mechanisms of action through which metformin may elicit anti-cancer effects are through
increases in TUNEL, which is an apoptosis biomarker and can reduce Ki-67, which is a biomarker 
of proliferation [46, 49]. Furthermore, metformin may contribute to weight loss through improving 
moderators of insulin resistance, regulation of fat oxidation, decreases in hepatic glucose output, 
and inhibition of gluconeogenesis. In turn, this positively impacts blood glucose control, and
reduces caloric intake and intestinal glucose absorption [50-52]. However, as to why metformin 
appears to elicit greater effects in children vs. adults, this requires more detailed evaluation, beyond











This meta-analysis has numerous strengths and limitations. Firstly, the foremost strength of the
present study is the use of only randomized-controlled trials to investigate the association between 
intervention and outcome. We investigated sources of heterogeneity among the included studies
using subgroup analyses, and were based on intervention duration, participants age and metformin
dose, and conducted a sensitivity analysis. However, there were some limitations that must be
     
      
     
      
 
 
      
    
  
      
   
        












addressed. Although we utilized a robust quality assessment tool, such judgements were qualitative
in nature, and inter-rater reliabilities were not further investigated. Another conceivable limitation
is the dearth of studies available for subgroup analysis, however, this was beyond the operational 
control of the study. This highlights that larger studies with adequately powered sample sizes are
needed to inform definitive conclusions. 
Conclusion
We found an overall non-significant decline in IGF-1 following metformin intake; however, a
significant degree of heterogeneity was observed among studies, attributable to intervention
duration (week) and study population. In sub-group analyses, in children, intervention duration 
˃12 weeks yielded significant reductions in IGF-1, whilst paradoxically, in participants >18 years 
old, metformin intake significantly increased IGF-1. We suggest that caution be taken when
interpreting the findings of this review, particularly given the discordant supplementation practices 
between children and adults. We strongly recommend that evidence from longitudinal studies is
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Fig. 1. Forest plot of randomized controlled trials investigating the effects of metformin on IGF-
1 levels.
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Fig2. A) Dose-response analysis - metformin dosage (IU/day) and Intervention duration (week) with 
IGF changes. Weighted mean difference, WMD., B) Meta regression analysis
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<1000 3 -3.890 -14.690 6.910 0.480 0.000 88.2
≥1000 8 0.232 -2.290 2.754 0.857 0.000 88.3
Intervention 
duration (week)
≤12 8 0.584 -1.884 3.053 0.643 0.000 87.4
˃12 3 -55.402 -79.845 -30.960 0.000 0.369 0.0
Age(years)
4 15.125 5.522 24.729 0.002 0.000 92.518 ˃
18 ≤ 7 -1.038 -3.578 1.502 0.423 0.000 78.0
Type of study
population
Cancer 3 -1.099 -3.779 1.581 0.422 0.028 71.9
Children 3 -55.402 -79.845 -30.960 0.000 0.369 0.0
women with 2 2.365 -10.672 15.402 0.722 0.286 12.3
polycystic ovary
syndrome
healthy 2 -2.206 -12.274 7.863 0.668 0.000 94.7
